IceCure Medical (ICCM) Stock Overview
A commercial stage medical device company, researches, develops, and markets cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
ICCM Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
IceCure Medical Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.01 |
| 52 Week High | US$1.66 |
| 52 Week Low | US$0.48 |
| Beta | 2.59 |
| 1 Month Change | -3.81% |
| 3 Month Change | -18.55% |
| 1 Year Change | 37.42% |
| 3 Year Change | -39.16% |
| 5 Year Change | 676.92% |
| Change since IPO | 840.41% |
Recent News & Updates
Recent updates
Is IceCure Medical (NASDAQ:ICCM) In A Good Position To Invest In Growth?
Jul 31
We're Keeping An Eye On IceCure Medical's (NASDAQ:ICCM) Cash Burn Rate
Nov 29Is IceCure Medical (NASDAQ:ICCM) In A Good Position To Deliver On Growth Plans?
Aug 08IceCure gains 19% on seeking FDA nod for cancer treatment
Oct 19IceCure files application for approval of ProSense in Canada for tumors
Jul 25Shareholder Returns
| ICCM | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 9.8% | 2.9% | 3.4% |
| 1Y | 37.4% | 9.6% | 13.7% |
Return vs Industry: ICCM exceeded the US Medical Equipment industry which returned 9.6% over the past year.
Return vs Market: ICCM exceeded the US Market which returned 13.7% over the past year.
Price Volatility
| ICCM volatility | |
|---|---|
| ICCM Average Weekly Movement | 8.4% |
| Medical Equipment Industry Average Movement | 8.9% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 4.0% |
Stable Share Price: ICCM has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ICCM's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 65 | Eyal Shamir | www.icecure-medical.com |
IceCure Medical Ltd, a commercial stage medical device company, researches, develops, and markets cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers ProSense system, a single probe system for the treatment of malignant breast tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors.
IceCure Medical Ltd Fundamentals Summary
| ICCM fundamental statistics | |
|---|---|
| Market cap | US$59.20m |
| Earnings (TTM) | -US$15.30m |
| Revenue (TTM) | US$3.27m |
Is ICCM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ICCM income statement (TTM) | |
|---|---|
| Revenue | US$3.27m |
| Cost of Revenue | US$1.87m |
| Gross Profit | US$1.40m |
| Other Expenses | US$16.70m |
| Earnings | -US$15.30m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.26 |
| Gross Margin | 42.77% |
| Net Profit Margin | -467.37% |
| Debt/Equity Ratio | 0% |
How did ICCM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/30 09:01 |
| End of Day Share Price | 2025/06/27 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
IceCure Medical Ltd is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Kemp Dolliver | Brookline Capital Markets |
| Yi Chen | H.C. Wainwright & Co. |
| Anthony Vendetti | Maxim Group |